Diabetic cardiomyopathy and diastolic heart failure - Difficulties with relaxation

Diabetes Research and Clinical Practice

Volumn 97, Issue 2, 2012, Pages 185-194

  Teupe, C ^a   Rosak, C ^b  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Diabetes mellitus; Diabetic cardiomyopathy; Diagnosis; Diastolic dysfunction; Heart failure; Treatment

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INCRETIN; INSULIN; LOSARTAN; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO;

BLOOD GLUCOSE MONITORING; BLOOD PRESSURE MONITORING; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR RISK; COLOR ULTRASOUND FLOWMETRY; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DIASTOLIC DYSFUNCTION; DIASTOLIC HEART FAILURE; DISEASE COURSE; EARLY INTERVENTION; ENERGY YIELD; FATTY ACID OXIDATION; GLYCEMIC CONTROL; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE RELAXATION; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; M MODE ECHOCARDIOGRAPHY; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; TISSUE DOPPLER IMAGING; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD GLUCOSE; BLOOD PRESSURE; DIABETIC CARDIOMYOPATHIES; DISEASE PROGRESSION; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE, DIASTOLIC; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; RISK FACTORS; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84865079375     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2012.03.008     Document Type: Review

References (81)

1. Kannel W.B., Hjortland M., Castelli W.P. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 1974, 34(1):29-34.
2. Stratton I.M., Adler A.I., Neil H.A., Matthews D.R., Manley S.E., Cull C.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000, 321(7258):405-412.
3. Gottdiener J.S., Arnold A.M., Aurigemma G.P., Polak J.F., Tracy R.P., Kitzman D.W., et al. Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol 2000, 35(6):1628-1637.
4. Nichols G.A., Gullion C.M., Koro C.E., Ephross S.A., Brown J.B. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 2004, 27(8):1879-1884.
5. Rubler S., Dlugash J., Yuceoglu Y.Z., Kumral T., Branwood A.W., Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 1972, 30(6):595-602.
6. Paulus W.J., Tschope C., Sanderson J.E., Rusconi C., Flachskampf F.A., Rademakers F.E., et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007, 28(20):2539-2550.
7. Karason K., Sjostrom L., Wallentin I., Peltonen M. Impact of blood pressure and insulin on the relationship between body fat and left ventricular structure. Eur Heart J 2003, 24(16):1500-1505.
8. Ingelsson E., Sundstrom J., Arnlov J., Zethelius B., Lind L. Insulin resistance and risk of congestive heart failure. JAMA 2005, 294(3):334-341.
9. Lee M., Gardin J.M., Lynch J.C., Smith V.E., Tracy R.P., Savage P.J., et al. Diabetes mellitus and echocardiographic left ventricular function in free-living elderly men and women: the Cardiovascular Health Study. Am Heart J 1997, 133(1):36-43.
10. Devereux R.B., Roman M.J., Paranicas M., O'Grady M.J., Lee E.T., Welty T.K., et al. Impact of diabetes on cardiac structure and function: the strong heart study. Circulation 2000, 101(19):2271-2276.
11. Liu J.E., Palmieri V., Roman M.J., Bella J.N., Fabsitz R., Howard B.V., et al. The impact of diabetes on left ventricular filling pattern in normotensive and hypertensive adults: the Strong Heart Study. J Am Coll Cardiol 2001, 37(7):1943-1949.
12. Boyer J.K., Thanigaraj S., Schechtman K.B., Perez J.E. Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus. Am J Cardiol 2004, 93(7):870-875.
13. Ashrafian H., Frenneaux M.P., Opie L.H. Metabolic mechanisms in heart failure. Circulation 2007, 116(4):434-448.
14. Maisch B., Alter P., Pankuweit S. Diabetic cardiomyopathy-fact or fiction?. Herz 2011, 36(2):102-115.
15. Rodrigues B., Cam M.C., McNeill J.H. Metabolic disturbances in diabetic cardiomyopathy. Mol Cell Biochem 1998, 180(1-2):53-57.
16. Russell R.R., Yin R., Caplan M.J., Hu X., Ren J., Shulman G.I., et al. Additive effects of hyperinsulinemia and ischemia on myocardial GLUT1 and GLUT4 translocation in vivo. Circulation 1998, 98(20):2180-2186.
17. Liedtke A.J., DeMaison L., Eggleston A.M., Cohen L.M., Nellis S.H. Changes in substrate metabolism and effects of excess fatty acids in reperfused myocardium. Circ Res 1988, 62(3):535-542.
18. Rijzewijk L.J., van der Meer R.W., Smit J.W., Diamant M., Bax J.J., Hammer S., et al. Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J Am Coll Cardiol 2008, 52(22):1793-1799.
19. Stratmann B., Tschoepe D. Heart in diabetes: not only a macrovascular disease. Diabetes Care 2011, 34(Suppl. 2):S138-S144.
20. Yim M.B., Yim H.S., Lee C., Kang S.O., Chock P.B. Protein glycation: creation of catalytic sites for free radical generation. Ann NY Acad Sci 2001, 928:48-53.
21. Park J.Y., Takahara N., Gabriele A., Chou E., Naruse K., Suzuma K., et al. Induction of endothelin-1 expression by glucose: an effect of protein kinase C activation. Diabetes 2000, 49(7):1239-1248.
22. Bian K., Doursout M.F., Murad F. Vascular system: role of nitric oxide in cardiovascular diseases. J Clin Hypertens (Greenwich) 2008, 10(4):304-310.
23. de Simone G., Gottdiener J.S., Chinali M., Maurer M.S. Left ventricular mass predicts heart failure not related to previous myocardial infarction: the Cardiovascular Health Study. Eur Heart J 2008, 29(6):741-747.
24. Chowdhry M.F., Vohra H.A., Galinanes M. Diabetes increases apoptosis and necrosis in both ischemic and nonischemic human myocardium: role of caspases and poly-adenosine diphosphate-ribose polymerase. J Thorac Cardiovasc Surg 2007, 134(1):124-131. 131.e1-3.
25. Chen S., Evans T., Mukherjee K., Karmazyn M., Chakrabarti S. Diabetes-induced myocardial structural changes: role of endothelin-1 and its receptors. J Mol Cell Cardiol 2000, 32(9):1621-1629.
26. Regan T.J., Lyons M.M., Ahmed S.S., Levinson G.E., Oldewurtel H.A., Ahmad M.R., et al. Evidence for cardiomyopathy in familial diabetes mellitus. J Clin Invest 1977, 60(4):884-899.
27. Avendano G.F., Agarwal R.K., Bashey R.I., Lyons M.M., Soni B.J., Jyothirmayi G.N., et al. Effects of glucose intolerance on myocardial function and collagen-linked glycation. Diabetes 1999, 48(7):1443-1447.
28. Berg T.J., Snorgaard O., Faber J., Torjesen P.A., Hildebrandt P., Mehlsen J., et al. Serum levels of advanced glycation end products are associated with left ventricular diastolic function in patients with type 1 diabetes. Diabetes Care 1999, 22(7):1186-1190.
29. Zieman S.J., Kass D.A. Advanced glycation endproduct crosslinking in the cardiovascular system: potential therapeutic target for cardiovascular disease. Drugs 2004, 64(5):459-470.
30. Bisognano J.D., Weinberger H.D., Bohlmeyer T.J., Pende A., Raynolds M.V., Sastravaha A., et al. Myocardial-directed overexpression of the human beta(1)-adrenergic receptor in transgenic mice. J Mol Cell Cardiol 2000, 32(5):817-830.
31. Wold L.E., Ceylan-Isik A.F., Ren J. Oxidative stress and stress signaling: menace of diabetic cardiomyopathy. Acta Pharmacol Sin 2005, 26(8):908-917.
32. Rota M., LeCapitaine N., Hosoda T., Boni A., De Angelis A., Padin-Iruegas M.E., et al. Diabetes promotes cardiac stem cell aging and heart failure, which are prevented by deletion of the p66shc gene. Circ Res 2006, 99(1):42-52.
33. Laakso M. Heart in diabetes: a microvascular disease. Diabetes Care 2011, 34(Suppl. 2):S145-S149.
34. From A.M., Scott C.G., Chen H.H. The development of heart failure in patients with diabetes mellitus and pre-clinical diastolic dysfunction: a population-based study. J Am Coll Cardiol 2010, 55(4):300-305.
35. Brooks B.A., Franjic B., Ban C.R., Swaraj K., Yue D.K., Celermajer D.S., et al. Diastolic dysfunction and abnormalities of the microcirculation in type 2 diabetes. Diabetes Obes Metab 2008, 10(9):739-746.
36. Poulsen M.K., Henriksen J.E., Dahl J., Johansen A., Gerke O., Vach W., et al. Left ventricular diastolic function in type 2 diabetes mellitus: prevalence and association with myocardial and vascular disease. Circ Cardiovasc Imaging 2010, 3(1):24-31.
37. Nakai H., Takeuchi M., Nishikage T., Lang R.M., Otsuji Y. Subclinical left ventricular dysfunction in asymptomatic diabetic patients assessed by two-dimensional speckle tracking echocardiography: correlation with diabetic duration. Eur J Echocardiogr 2009, 10(8):926-932.
38. Ernande L., Bergerot C., Rietzschel E.R., De Buyzere M.L., Thibault H., Pignonblanc P.G., et al. Diastolic dysfunction in patients with type 2 diabetes mellitus: is it really the first marker of diabetic cardiomyopathy?. J Am Soc Echocardiogr 2011, 24(11):1268-12750.
39. Fonseca C.G., Dissanayake A.M., Doughty R.N., Whalley G.A., Gamble G.D., Cowan B.R., et al. Three-dimensional assessment of left ventricular systolic strain in patients with type 2 diabetes mellitus, diastolic dysfunction, and normal ejection fraction. Am J Cardiol 2004, 94(11):1391-1395.
40. Bhatia R.S., Tu J.V., Lee D.S., Austin P.C., Fang J., Haouzi A., et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006, 355(3):260-269.
41. Gustafsson I., Brendorp B., Seibaek M., Burchardt H., Hildebrandt P., Kober L., et al. Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure. J Am Coll Cardiol 2004, 43(5):771-777.
42. Bertoni A.G., Hundley W.G., Massing M.W., Bonds D.E., Burke G.L., Goff D.C. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 2004, 27(3):699-703.
43. Berry C., Brett M., Stevenson K., McMurray J.J., Norrie J. Nature and prognostic importance of abnormal glucose tolerance and diabetes in acute heart failure. Heart 2008, 94(3):296-304.
44. Fang Z.Y., Yuda S., Anderson V., Short L., Case C., Marwick T.H. Echocardiographic detection of early diabetic myocardial disease. J Am Coll Cardiol 2003, 41(4):611-617.
45. Kass D.A., Bronzwaer J.G., Paulus W.J. What mechanisms underlie diastolic dysfunction in heart failure?. Circ Res 2004, 94(12):1533-1542.
46. Zile M.R., Baicu C.F., Gaasch W.H. Diastolic heart failure-abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 2004, 350(19):1953-1959.
47. Vizzardi E., Bonadei I., Teli M., Caretta G., Maiandi C., Madureri A., et al. Usefulness of left atrial diametres and volumes for the evaluation of left ventricular diastolic function. Recenti Prog Med 2009, 100(6):294-298.
48. Mandinov L., Eberli F.R., Seiler C., Hess O.M. Diastolic heart failure. Cardiovasc Res 2000, 45(4):813-825.
49. Steine K., Stugaard M., Smiseth O.A. Mechanisms of retarded apical filling in acute ischemic left ventricular failure. Circulation 1999, 99(15):2048-2054.
50. Nagueh S.F., Middleton K.J., Kopelen H.A., Zoghbi W.A., Quinones M.A. Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. J Am Coll Cardiol 1997, 30(6):1527-1533.
51. Urheim S., Edvardsen T., Torp H., Angelsen B., Smiseth O.A. Myocardial strain by Doppler echocardiography. Validation of a new method to quantify regional myocardial function. Circulation 2000, 102(10):1158-1164.
52. Ng A.C., Delgado V., Bertini M., van der Meer R.W., Rijzewijk L.J., Shanks M., et al. Findings from left ventricular strain and strain rate imaging in asymptomatic patients with type 2 diabetes mellitus. Am J Cardiol 2009, 104(10):1398-1401.
53. Jellis C., Martin J., Narula J., Marwick T.H. Assessment of nonischemic myocardial fibrosis. J Am Coll Cardiol 2010, 56(2):89-97.
54. Perez J.E., McGill J.B., Santiago J.V., Schechtman K.B., Waggoner A.D., Miller J.G., et al. Abnormal myocardial acoustic properties in diabetic patients and their correlation with the severity of disease. J Am Coll Cardiol 1992, 19(6):1154-1162.
55. Schmidt A.R., Friedrich M.G. Imaging targets in diabetic cardiomyopathy: current status and perspective. Can J Diab 2011, 35(4):353-362.
56. Bhalla M.A., Chiang A., Epshteyn V.A., Kazanegra R., Bhalla V., Clopton P., et al. Prognostic role of B-type natriuretic peptide levels in patients with type 2 diabetes mellitus. J Am Coll Cardiol 2004, 44(5):1047-1052.
57. Maisel A.S., McCord J., Nowak R.M., Hollander J.E., Wu A.H., Duc P., et al. Bedside B-type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study. J Am Coll Cardiol 2003, 41(11):2010-2017.
58. Eshaghian S., Horwich T.B., Fonarow G.C. An unexpected inverse relationship between HbA1c levels and mortality in patients with diabetes and advanced systolic heart failure. Am Heart J 2006, 151(1):91.
59. von Bibra H., Siegmund T., Hansen A., Jensen J., Schumm-Draeger P.M. Augmentation of myocardial function by improved glycemic control in patients with type 2 diabetes mellitus. Dtsch Med Wochenschr 2007, 132(14):729-734.
60. Konduracka E., Gackowski A., Rostoff P., Galicka-Latala D., Frasik W., Piwowarska W. Diabetes-specific cardiomyopathy in type 1 diabetes mellitus: no evidence for its occurrence in the era of intensive insulin therapy. Eur Heart J 2007, 28(20):2465-2471.
61. Murcia A.M., Hennekens C.H., Lamas G.A., Jimenez-Navarro M., Rouleau J.L., Flaker G.C., et al. Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction. Arch Intern Med 2004, 164(20):2273-2279.
62. Masoudi F.A., Inzucchi S.E., Wang Y., Havranek E.P., Foody J.M., Krumholz H.M. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 2005, 111(5):583-590.
63. Delea T.E., Edelsberg J.S., Hagiwara M., Oster G., Phillips L.S. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. Diabetes Care 2003, 26(11):2983-2989.
64. Eurich D.T., McAlister F.A., Blackburn D.F., Majumdar S.R., Tsuyuki R.T., Varney J., et al. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ 2007, 335(7618):497.
65. Karter A.J., Ahmed A.T., Liu J., Moffet H.H., Parker M.M. Pioglitazone initiation and subsequent hospitalization for congestive heart failure. Diabet Med 2005, 22(8):986-993.
66. Eurich D.T., Majumdar S.R., McAlister F.A., Tsuyuki R.T., Johnson J.A. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 2005, 28(10):2345-2351.
67. Inzucchi S.E., Masoudi F.A., Wang Y., Kosiborod M., Foody J.M., Setaro J.F., et al. Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: insights from the National Heart Care Project. Diabetes Care 2005, 28(7):1680-1689.
68. Thrainsdottir I., Malmberg K., Olsson A., Gutniak M., Ryden L. Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure. Diab Vasc Dis Res 2004, 1(1):40-43.
69. Fragasso G., Palloshi A., Puccetti P., Silipigni C., Rossodivita A., Pala M., et al. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J Am Coll Cardiol 2006, 48(5):992-998.
70. Al-Shafei A.I., Wise R.G., Gresham G.A., Carpenter T.A., Hall L.D., Huang C.L. Magnetic resonance imaging analysis of cardiac cycle events in diabetic rats: the effect of angiotensin-converting enzyme inhibition. J Physiol 2002, 538(Pt 2):555-572.
71. Kawasaki D., Kosugi K., Waki H., Yamamoto K., Tsujino T., Masuyama T. Role of activated renin-angiotensin system in myocardial fibrosis and left ventricular diastolic dysfunction in diabetic patients-reversal by chronic angiotensin II type 1A receptor blockade. Circ J 2007, 71(4):524-529.
72. Orea-Tejeda A., Colin-Ramirez E., Castillo-Martinez L., Asensio-Lafuente E., Corzo-Leon D., Gonzalez-Toledo R., et al. Aldosterone receptor antagonists induce favorable cardiac remodeling in diastolic heart failure patients. Rev Invest Clin 2007, 59(2):103-107.
73. Shindler D.M., Kostis J.B., Yusuf S., Quinones M.A., Pitt B., Stewart D., et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol 1996, 77(11):1017-1020.
74. Dahlof B., Zanchetti A., Diez J., Nicholls M.G., Yu C.M., Barrios V., et al. Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. J Hypertens 2002, 20(9):1855-1864.
75. Schmieder R.E., Martus P., Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA 1996, 275(19):1507-1513.
76. Shekelle P.G., Rich M.W., Morton S.C., Atkinson C.S., Tu W., Maglione M., et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 2003, 41(9):1529-1538.
77. Carr A.A., Kowey P.R., Devereux R.B., Brenner B.M., Dahlof B., Ibsen H., et al. Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies. Am J Cardiol 2005, 96(11):1530-1536.
78. Yusuf S., Pfeffer M.A., Swedberg K., Granger C.B., Held P., McMurray J.J., et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003, 362(9386):777-781.
79. Fonarow G.C. Managing the patient with diabetes mellitus and heart failure: issues and considerations. Am J Med 2004, 116(Suppl. 5A):76S-88S.
80. Ryden L., Standl E., Bartnik M., Van den Berghe G., Betteridge J., de Boer M.J., et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007, 28(1):88-136.
81. Deedwania P.C., Giles T.D., Klibaner M., Ghali J.K., Herlitz J., Hildebrandt P., et al. Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF. Am Heart J 2005, 149(1):159-167.